MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Candesartan

Search medical newsFind research, conditions and clinical updates
  • Home
  • Candesartan
Candesartan 16 mg Emerges as a Robust, Evidence-Based Option for Migraine Prophylaxis
Posted inNeurology news

Candesartan 16 mg Emerges as a Robust, Evidence-Based Option for Migraine Prophylaxis

Posted by By MedXY 12/23/2025
A Phase 2 triple-blind trial confirms that 16 mg of candesartan daily significantly reduces monthly migraine days compared to placebo, offering a well-tolerated oral alternative for patients with episodic migraine.
Read More
Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial
Posted inNeurology news Specialties

Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial

Posted by By MedXY 09/21/2025
A multi-center, triple-blind phase 2 trial demonstrates that daily candesartan 16 mg significantly reduces migraine days in episodic migraine patients, with tolerable safety profiles, supporting its role as an effective preventive option.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Precision in Energy Assessment: A New Resting Metabolic Rate Equation Tailored for Elite Cyclists
  • Safety and Effectiveness of High-Dose OnabotulinumtoxinA for Limb Spasticity: A Prospective Observational Study
  • Postoperative Pain After Dental Procedures: Insights from the National Dental Practice-Based Research Network Using a Mobile Health Platform
  • Dual Remission of Atopic Dermatitis and Frequently Relapsing Nephrotic Syndrome With Dupilumab
  • When and How to Image Polymyalgia Rheumatica: International Recommendations for a Targeted, Evidence-Based Approach
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top